利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.017 秒)

    Cells expressing recombinant growth factor receptors
    1.
    发明授权
    Cells expressing recombinant growth factor receptors 有权

    公开(公告)号：US11530386B2

    公开(公告)日：2022-12-20

    申请号：US16061435

    申请日：2016-12-15

    申请人： INSTIL BIO (UK) LIMITED

    发明人： John Stephen Bridgeman

    IPC分类号： C07K14/705 ,  C12N5/00 ,  C07K14/71 ,  C12N5/0783 ,  A61K35/17 ,  C12N15/86

    摘要： The present invention discloses cell lines and recombinant growth factor receptors useful in adoptive cell therapy (ACT), wherein the recombinant growth factor receptor can act as a molecular switch enabling cells expressing the rGFR protein to be expanded in-vitro or in- vivo. Thus the invention provides a T or NK cell, comprising a recombinant growth factor receptor (rGFR) comprising: (i) an extracellular (EC) domain; (ii) a thrombopoietin receptor transmembrane (TM) domain; and (iii) a growth factor receptor intracellular (IC) domain.

    TUMOUR INFILTRATING LYMPHOCYTE THERAPY AND USES THEREOF
    3.
    发明申请
    TUMOUR INFILTRATING LYMPHOCYTE THERAPY AND USES THEREOF 有权

    公开(公告)号：US20220378826A1

    公开(公告)日：2022-12-01

    申请号：US17570556

    申请日：2022-01-07

    申请人： Instil Bio (UK) Limited

    发明人： Nicola Kaye Price ,  John Stephen Bridgeman

    IPC分类号： A61K35/17 ,  A61K38/17 ,  A61P35/00 ,  C12N5/0783 ,  G01N33/50

    摘要： The present invention concerns a biomarker useful in adoptive cell therapy. The biomarker in question is CD150, otherwise termed SLAM or SLAMF1. Herein Applicants demonstrate that expression of CD150 on tumour infiltrating lymphocytes infusion products correlates with the response rate seen in those patients. High CD150 expression is found on patients who go on to have a complete response and low expression on patients who do not respond to therapy. The invention relates to the use of the biomarker to predict response rate or stratify patients for treatment. It also covers exploitation of this receptor in adoptive cell therapy regimens in general, including but not limited to over expression of the receptor in T-cell populations or isolation of cells expressing CD150 in an effort to increase efficacy.